- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
42 result(s) found for: Testis.
Displaying page 1 of 3.
EudraCT Number: 2010-021898-36 | Sponsor Protocol Number: INT 38/10 | Start Date*: 2010-10-20 | ||||||||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | ||||||||||||||||||
Full Title: Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment. | ||||||||||||||||||
Medical condition: Patients with metastatic germ-cell tumors failing first-line treatment. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004075-23 | Sponsor Protocol Number: SWENOTECA-ABC-1 | Start Date*: 2015-02-26 | |||||||||||
Sponsor Name:St Olavs University Hospital | |||||||||||||
Full Title: A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer | |||||||||||||
Medical condition: Stage I, Seminomatous, Testicular cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004458-27 | Sponsor Protocol Number: Krypto-3 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Optimizing the fertility potential of bilateral cryptorchidism by treatment with adjuvant kryptocur. | |||||||||||||
Medical condition: Cryptorchidism | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002945-41 | Sponsor Protocol Number: 78464317 | Start Date*: 2020-09-24 | ||||||||||||||||||||||||||
Sponsor Name:Lone Nikolajsen | ||||||||||||||||||||||||||||
Full Title: The use of intraoperative methadone in children undergoing open urological surgery | ||||||||||||||||||||||||||||
Medical condition: Postoperative pain in children undergoing open urological surgery | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | |||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000894-19 | Sponsor Protocol Number: CA209-647 | Start Date*: 2016-09-28 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL) | ||||||||||||||||||
Medical condition: Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) FR (Completed) DE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-005481-18 | Sponsor Protocol Number: BNT142-01 | Start Date*: 2022-04-28 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:BioNTech SE | ||||||||||||||||||||||||||||||||||||||
Full Title: First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced sol... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Claudin 6 (CLDN6)-positive advanced solid tumors | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004323-20 | Sponsor Protocol Number: BNT211-01 | Start Date*: 2020-06-30 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:BioNTech Cell & Gene Therapies GmbH | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: CLDN6-positive relapsed or refractory advanced solid tumors | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) NL (Ongoing) SE (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004630-38 | Sponsor Protocol Number: HydroceleAlkScler | Start Date*: 2021-05-20 | ||||||||||||||||
Sponsor Name:Region Jämtland/Härjedalen | ||||||||||||||||||
Full Title: Sclerotherapy for hydro and spermatoceles with 99.5% Ethanol, an open clinical multicenter dose escalation study, phase 2 | ||||||||||||||||||
Medical condition: Hydrocele and Spermatocele | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000731-28 | Sponsor Protocol Number: EORTC 30983 | Start Date*: 2006-03-23 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: A Randomised Phase II/III Study of Taxol-BEP Versus BEP in Patients with Intermediate Prognosis Germ Cell Cancer | |||||||||||||
Medical condition: Patients with Intermediate Prognosis Germ cell Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004508-36 | Sponsor Protocol Number: FM-12-GCT01 | Start Date*: 2013-05-04 | |||||||||||
Sponsor Name:Fondazione Michelangelo - Avanzamento dello studio e cura dei tumori | |||||||||||||
Full Title: Brentuximab vedotin (SGN-35) as salvage therapy for males with advanced and platinum-resistant germ-cell tumors. An open label, single group, Phase 2 trial | |||||||||||||
Medical condition: Patients with histologically-confirmed germ-cell cancer with exclusive or prevalent CD30-positive embryonal carcinoma component | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004667-61 | Sponsor Protocol Number: SUITE - CUOG-TE 05 | Start Date*: 2007-02-22 | |||||||||||
Sponsor Name:Universitätsklinikum Hamburg-Eppendorf | |||||||||||||
Full Title: Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study | |||||||||||||
Medical condition: germ cell cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005607-13 | Sponsor Protocol Number: NN8640-4467 | Start Date*: 2022-07-15 | ||||||||||||||||||||||||||
Sponsor Name:NOVO NORDISK. S.P.A. | ||||||||||||||||||||||||||||
Full Title: A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with ... | ||||||||||||||||||||||||||||
Medical condition: Short stature born small for gestational age Turner syndrome Noonan syndrome Idiopathic short stature | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) SI (Ongoing) IE (Completed) DE (Ongoing) FI (Ongoing) GR (Ongoing) NL (Ongoing) BE (Ongoing) AT (Ongoing) ES (Ongoing) PT (Ongoing) BG (Ongoing) PL (Ongoing) LV (Ongoing) HR (Ongoing) LT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006295-29 | Sponsor Protocol Number: ICR-CTSU/2008/10019 | Start Date*: 2009-08-20 | |||||||||||
Sponsor Name:The Institute of Cancer Research [...] | |||||||||||||
Full Title: A single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT) | |||||||||||||
Medical condition: Patients with newly diagnosed NSGCTT or mixed GCT (MGCT) with vascular invasion and stage 1 disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004450-28 | Sponsor Protocol Number: T109/2012 | Start Date*: 2013-02-18 | ||||||||||||||||
Sponsor Name:University of Turku [...] | ||||||||||||||||||
Full Title: Effect of chemotherapy on endothelial function in patients with testicular cancer | ||||||||||||||||||
Medical condition: Testicular cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: FI (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004632-38 | Sponsor Protocol Number: GCTSK005 | Start Date*: 2017-11-09 | |||||||||||||||||||||
Sponsor Name:Národný onkologický ústav | |||||||||||||||||||||||
Full Title: Phase II study of Avelumab in multiple relapsed/refractory testicular germ cell cancer. | |||||||||||||||||||||||
Medical condition: Extracranial primary germ cell cancer, seminoma, or nonseminoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: SK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004418-32 | Sponsor Protocol Number: TestisCAB | Start Date*: 2016-03-16 | |||||||||||
Sponsor Name:Oslo University Hospital - Cancer Department | |||||||||||||
Full Title: Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer. | |||||||||||||
Medical condition: Cisplatin-resistant germ cell cancer of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) DK (Ongoing) SE (Ongoing) NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005223-18 | Sponsor Protocol Number: NRA6280030 | Start Date*: 2005-05-12 |
Sponsor Name:Childrens´ Hospital Erlangen | ||
Full Title: Evaluation of growth response in short children suffering from a disease with growth retardation and treated with Somatropin: A prospective, longitudinal non-randomised, open, phase II study | ||
Medical condition: Genotropin®) is approved for treatment of short statured children in specific indications. A benefit can also be achieved in other pathological conditions that lead to growth retardation. Because ... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000286-36 | Sponsor Protocol Number: IGR2012/1950 | Start Date*: 2014-04-02 |
Sponsor Name:Gustave Roussy | ||
Full Title: A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic non-seminomatous germ-cell tumors | ||
Medical condition: patients with pre-treated metastatic and /or primary mediastinal non-seminomatous germ-cell tumors | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001507-19 | Sponsor Protocol Number: 04/5/025 | Start Date*: 2005-05-22 |
Sponsor Name:National Children's Hospital & Trinity College Dublin | ||
Full Title: Treatment with recombinant Growth Hormone in Children born Small for Gestational Age (SGA) without Catch-up Growth. | ||
Medical condition: Short stature in children born small for gestational age without catch up growth | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005840-87 | Sponsor Protocol Number: SAKK0110 | Start Date*: 2013-10-10 |
Sponsor Name:Swiss Group for Clinical Cancer Research SAKK | ||
Full Title: Carboplatin chemotherapy and involved node radiotherapy in stage IIA/B seminoma | ||
Medical condition: Patients with seminoma stage IIA/B, after orchidectomy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.